Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 5
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.
Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Mohan M, et al. Among authors: gundarlapalli s. Am J Hematol. 2022 Dec;97(12):E451-E453. doi: 10.1002/ajh.26728. Epub 2022 Sep 24. Am J Hematol. 2022. PMID: 36097868 Free article. No abstract available.
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma.
Yarlagadda L, Gundarlapalli S, Parikh R, Landes RD, Kottarathara M, Ogunsesan Y, Hoque S, Mitma AA, Bailey C, Hill KM, Thanendrarajan S, Graziutti M, Mohan M, Zangari M, van Rhee F, Tricot G, Schinke C. Yarlagadda L, et al. Among authors: gundarlapalli s. Cancers (Basel). 2021 Aug 10;13(16):4019. doi: 10.3390/cancers13164019. Cancers (Basel). 2021. PMID: 34439174 Free PMC article.
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Mohan M, et al. Among authors: gundarlapalli s. Am J Hematol. 2022 Jul;97(7):E276-E280. doi: 10.1002/ajh.26580. Epub 2022 May 2. Am J Hematol. 2022. PMID: 35472167 Free PMC article. No abstract available.
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.
Larsen K, Spencer H, Mohan M, Bailey C, Hill K, Kottarathara M, Parikh R, Hoque S, Erra A, Mitma AA, Mathur P, Yarlagadda L, Gundarlapalli S, Ogunsesan Y, Hussain M, Thalambedu N, Sehti J, Al Hadidi S, Thanendrarajan S, Graziutti M, Zangari M, Barlogie B, van Rhee F, Tricot G, Schinke C. Larsen K, et al. Among authors: gundarlapalli s. J Clin Med. 2022 Mar 16;11(6):1640. doi: 10.3390/jcm11061640. J Clin Med. 2022. PMID: 35329966 Free PMC article.
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Mohan M, et al. Among authors: gundarlapalli s. Am J Hematol. 2022 Jun 1;97(6):E195-E198. doi: 10.1002/ajh.26530. Epub 2022 Mar 21. Am J Hematol. 2022. PMID: 35285981 Free article. No abstract available.
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C. Baker D, et al. Among authors: gundarlapalli s. Haematologica. 2021 Dec 1;106(12):3215-3218. doi: 10.3324/haematol.2021.278779. Haematologica. 2021. PMID: 34847659 Free PMC article. No abstract available.
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C. Baker D, et al. Among authors: gundarlapalli s. Haematologica. 2021 Aug 12. doi: 10.3324/haematol.278779. Online ahead of print. Haematologica. 2021. PMID: 34382384
Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials.
Yarlagadda N, Gundarlapalli S, Sharma S, Suelzer E, Abid MB, Abdallah AO, Schinke C, Atrash S, Mohan M. Yarlagadda N, et al. Among authors: gundarlapalli s. Leuk Res. 2021 Nov;110:106714. doi: 10.1016/j.leukres.2021.106714. Epub 2021 Sep 25. Leuk Res. 2021. PMID: 34598075 No abstract available.